Update information

Minor changes since publication

September 2025: We added links to relevant technology appraisal guidance in the section on metastatic pancreatic cancer. We also simplified the guideline by removing recommendations on general principles of care that are covered in other NICE guidelines.

December 2024: In September 2024, supplies of pancreatic enzyme replacement therapy were disrupted, so availability varies. The latest information on prescribing and ordering was added to the section on nutritional management.

August 2023: As part of our work to make our guidance more useful and usable, we are testing out some changes to improve the way we present our guidance.

The recommendations from the technology appraisal guidance on nab-paclitaxel with gemcitabine (TA476) have been brought into this guideline.

ISBN: 978-1-4731-2794-4